Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586924 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00586924 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 49 participants.
The verdict
NCT00586924, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
A dose-escalation study to identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), defined as the highest dose that can safely be given to a participant and establish the safest dose based on the highest tolerated dose for clinical testing.
Interventions
- DRUG Moxetumomab Pasudotox (CAT 8015)
- DRUG CAT 8015 (Moxetumomab Pasudotox)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-05-10 |
| Est. Completion | 2015-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00586924
The ClinicalTrials.gov registry entry for NCT00586924 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Moxetumomab Pasudotox (CAT 8015) is the first listed.
NCT00586924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00586924 about?
NCT00586924 is a clinical study titled "A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia". A dose-escalation study to identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), defined as the highest dose that can safely be given to a participant and establish the safest dose based on the highest tolerated dose for clinical testing.
What is the current status of trial NCT00586924?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2007-05-10. Estimated completion is 2015-05-06.
What interventions are being tested in trial NCT00586924?
The interventions under investigation include: Moxetumomab Pasudotox (CAT 8015) (DRUG), CAT 8015 (Moxetumomab Pasudotox) (DRUG).
Who is sponsoring clinical trial NCT00586924?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.